Rome, Italy

Antonaroli Simonetta

This inventor holds 1 USPTO granted patent. Top assignee: Istituto Chimico Internazionale Dr. Giuseppe Rende S.r.l.. Active years: 1993.


% Patents Active = 100.0

Average Co-Inventor Count = 5.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 1993

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Antonaroli Simonetta: Innovator in Pharmaceutical Chemistry

Introduction

Antonaroli Simonetta is a notable inventor based in Rome, Italy. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds related to acetazolamide. His work focuses on creating innovative solutions for medical treatments.

Latest Patents

Simonetta holds a patent for "Acetazolamide-related compounds, process for their preparation, and compounds related to acetazolamide and to its N-methyl derivatives." This patent describes compounds that serve as inhibitors of carbonic anhydrase, similar to acetazolamide. These compounds are particularly noteworthy because they are well absorbed topically, making them suitable for use as drugs in treating glaucoma. He has 1 patent to his name.

Career Highlights

Simonetta is associated with the Istituto Chimico Internazionale Dr. Giuseppe Rende S.r.l., where he continues to advance his research and development efforts. His work has the potential to impact the treatment of various medical conditions, particularly those related to eye health.

Collaborations

Throughout his career, Simonetta has collaborated with esteemed colleagues, including Bianco Armandodariano and Mario Brufani. These partnerships have fostered a collaborative environment that enhances innovation and research outcomes.

Conclusion

Antonaroli Simonetta is a distinguished inventor whose work in pharmaceutical chemistry is paving the way for new treatments in glaucoma care. His innovative compounds and dedication to research exemplify the spirit of invention in the medical field.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…